BioSpace News Archive

Ascletis Pharma Inc. announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease inhibitor, demonstrated potential to be effective treatment for COVID-19.

Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.

GC corp. announced that it has signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc., a pioneering US-based contract development and manufacturing organization that designs and develops scalable cell and gene technologies.

NTC Srl, R&D driven pharmaceutical company with headquarters in Italy announces the submission of the marketing authorisation application through the European Decentralised Procedure for its development product NTC015 for bowel preparation for colonoscopy.

BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.

BeiGene announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus placebo as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer, at the virtual American Society of Clinical Oncology Plenary Series on April 19, 2022.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the comprehensive launch of the Axonics F15 across the United States.

Turnstone Biologics Corp. announced the appointments of Venkat Ramanan, Ph.D., as Chief Financial Officer, and P. Joseph Campisi Jr., J.D., M.B.A., as General Counsel.

Johnson & Johnson announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.

Johnson & Johnson announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds.